Can a Patient's own immune cells fight advanced cancer?

NCT ID NCT05087745

Recruiting now Disease control Sponsor: Shanghai Juncell Therapeutics Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. The study aims to assess the safety and effectiveness of this cell therapy, including how well it shrinks tumors and how long any response lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tumor-infiltrating lymphocytes (TILs)
What this could lead to: If successful, this approach could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-stage trial with a small number of participants, so results may not apply broadly. TIL therapy can cause significant side effects, including immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR EFFECTS OF IMMUNOTHERAPY TREATMENT SIDE EFFECTS TUMOR INFILTRATING LYMPHOCYTES

Contacts and locations

Locations

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.